SARONNI, DAVIDE
SARONNI, DAVIDE
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
Effects of human recombinant type I IFNs (IFN-α2b and IFN-β1a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis : a preliminary study
2018-01-01 A. Dicitore, S. Castiglioni, D. Saronni, D. Gentilini, M.O. Borghi, S. Stabile, M. Vignali, A.M. Di Blasio, L. Persani, G. Vitale
Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study
2020-01-01 A. Dicitore, M.C. Cantone, G. Gaudenzi, D. Saronni, S. Carra, M.O. Borghi, M. Albertelli, D. Ferone, L.J. Hofland, L. Persani, G. Vitale
Precision medicine in neuroendocrine neoplasms : an update on current management and future perspectives
2019-07-01 G. Gaudenzi, A. Dicitore, S. Carra, D. Saronni, C. Pozza, E. Giannetta, L. Persani, G. Vitale
Role of epigenetic therapy in the modulation of tumor growth and migration in human castration-resistant prostate cancer cells with neuroendocrine differentiation
2021-08-02 A. Dicitore, M.G. Bacalini, D. Saronni, G. Gaudenzi, M.C. Cantone, G. Gelmini, E.S. Grassi, D. Gentilini, M.O. Borghi, A.M. Di Blasio, L. Persani, P. Garagnani, C. Franceschi, G. Vitale
Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications
2021-04-14 G. Vitale, A. Cozzolino, P. Malandrino, R. Minotta, G. Puliani, D. Saronni, A. Faggiano, A. Colao
TYROSINE KINASE INHIBITORS IN NEUROENDOCRINE TUMORS: FROM IN VITRO TO ZEBRAFISH MODEL
2022-04-21 D. Saronni
Vandetanib versus cabozantinib in medullary thyroid carcinoma: A focus on anti‐angiogenic effects in zebrafish model
2021-03-16 S. Carra, G. Gaudenzi, A. Dicitore, D. Saronni, M.C. Cantone, A. Plebani, A. Ghilardi, M.O. Borghi, L.J. Hofland, L. Persani, G. Vitale